Evidence map›Paper›PMID 31653965›Full record

ArticleScientific reports2019

Molecular signatures associated with prostate cancer cell line (PC-3) exposure to inactivated Zika virus.

Jeany Delafiori, Estela de Oliveira Lima, Mohamed Ziad Dabaja, Flávia Luísa Dias-Audibert, Diogo Noin de Oliveira, Carlos Fernando Odir Rodrigues Melo, Karen Noda Morishita, Geovana Manzan Sales, Ana Lucia Tasca Gois Ruiz, Gisele Goulart da Silva and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jeany DelafioriInnovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-2481-0465
Estela de Oliveira LimaMedical School, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
Mohamed Ziad DabajaInnovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Flávia Luísa Dias-AudibertInnovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-5758-2070
Diogo Noin de OliveiraInnovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Carlos Fernando Odir Rodrigues MeloInnovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-0334-1065
Karen Noda MorishitaInnovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Geovana Manzan SalesInnovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Ana Lucia Tasca Gois RuizSchool of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Gisele Goulart da SilvaDepartment of Physiological Sciences, Piracicaba Dental School, University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
Marcelo LancellottiLaboratory of Biotechnology, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Rodrigo Ramos CatharinoInnovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil. rodrigo.catharino@fcf.unicamp.br.ORCID http://orcid.org/0000-0001-7219-2644
Universidade Estadual de Campinas (UNICAMP) · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent outbreak of Zika virus (ZIKV) infection associated with microcephaly cases has elicited much research on the mechanisms involved in ZIKV-host cell interactions. It has been described that Zika virus impairs cell growth, raising a hypothesis about its oncolytic potential against cancer cells. ZIKV tumor cell growth inhibition was later confirmed for glioblastoma. It was also demonstrated that an inactivated ZIKV prototype (ZVp) based on bacterial outer membrane vesicles has antiproliferative activity upon other cancer cell lines, such as PC-3 prostate cancer cell. This study aims at understanding the pathways that might be involved with the antiproliferative effect of Zika virus against prostate cancer cells. A metabolomic approach based on high-resolution mass spectrometry analysis led to the identification of 21 statistically relevant markers of PC-3 cells treated with ZVp. The markers were associated with metabolic alterations that trigger lipid remodeling, endoplasmic reticulum stress, inflammatory mediators, as well as disrupted porphyrin and folate metabolism. These findings highlight molecular signatures of ZVp-induced response that may be involved on cellular pathways triggered by its antiproliferative effect. To our knowledge, this is the first reported metabolomic assessment of ZIKV effect on prostate cancer cells, a promising topic for further research.

Indexed as

Virus InactivationDiscriminant AnalysisHumansLeast-Squares AnalysisLipid MetabolismMalePC-3 CellsProstatic NeoplasmsZika Virus

Identifiers

PMID31653965
PMCPMC6814752
OpenAlexW2982200622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.